HYPHEN BioMed

À propos

The French company Hyphen BioMed is a well-known European company in the field of biochemical’s, immunological, in vitro research and diagnostic reagents for the exploration of Thrombosis, Haemostasis, Fibrinolysis and Auto-Immune disorders associated with thrombosis diseases. Hyphen BioMed is expanding rapidly, and one of its major goals, in addition to its growing presence in Europe through distributors such as COACHROM, Diagnostica CZ, Nodia, Menarini or Quadratech, is to be introduced on the North American market through its close partnership with Aniara Corporation. Aniara is dedicated to introduce new laboratory tools and diagnostic methods to clinical laboratories, academic research institutes, biotech and pharmaceutical companies in North America. Hyphen BioMed and Aniara are looking forward to establish a major technical and scientific partnership with any organization involved in clinical diagnosis, medical research or drug development, especially for new drugs designed for fighting thrombosis diseases or managing bleeding risk, as well as for monitoring therapies developed for managing these complications. Hyphen BioMed and Aniara are committed to listen to new clinical and research requests, and combine their in-depth experience and their understanding of laboratory requirements in order to offer the most updated laboratory methods and in vitro testing tools to today’s laboratories and researchers. An important characteristic of Hyphen BioMed and Aniara is the strong relationship with academic research and new technological developments, through direct partnerships. On October 26th, 2010, the company was acquired by Sysmex Co. (Japan), but it continues running its own business model through its distributors's network.